Raphaël Ognar on Adding New Options to the Oncologic Cell Therapy Arsenal
The cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.
Raphaël Ognar on Developing CIR-NK Cells to Better Target Cancer Cells
The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.
Pursuing Strategic Partnerships in Cell Therapy
Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.